drugset / Trial / NCT00445055

Evaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea

NCT00445055

RandomizedParallel-groupDouble-blindPrevention

Summary

In this prospective, randomised, placebo-controlled study, the researchers determined whether 0.625 mg or 2.5 mg of IV droperidol given 30 min before emergence from general anaesthesia reduces the incidence of immediate and delayed post operative nausea and vomiting (PONV) in thyroid surgical female population. Two hundred and forty six female patients receiving general anaesthesia for thyroid surgery received either droperidol 0.625 mg or droperidol 2.5 mg or placebo before emergence.

Timeline

Start
2007-04
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Droperidol Small molecule 0.625 mg Intravenous
Subject Droperidol Small molecule 2.5 mg Intravenous

Indications

No indication recorded.